Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Pretargeted Imaging beyond the Blood-Brain Barrier-Utopia or Feasible?

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Potential Targeted Therapies in Ovarian Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Recent Advances in the Development of Tetrazine Ligation Tools for Pretargeted Nuclear Imaging

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Exploration of Symptom Scale as an Outcome for Deprescribing: A Medication Review Study in Nursing Homes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Development of 18F-Labeled Bispyridyl Tetrazines for In Vivo Pretargeted PET Imaging

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Psychedelics and Neural Plasticity: Therapeutic Implications

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Bioorthogonal Click of Colloidal Gold Nanoparticles to Antibodies In vivo

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Mapping neurotransmitter systems to the structural and functional organization of the human neocortex

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Sara Lopes van den Broek
  • Vladimir Shalgunov
  • Rocío García Vázquez
  • Natalie Beschorner
  • Natasha S R Bidesi
  • Maiken Nedergaard
  • Gitte M Knudsen
  • Dag Sehlin
  • Stina Syvänen
  • Matthias M Herth
Vis graf over relationer

Pretargeting is a promising nuclear imaging technique that allows for the usage of antibodies (Abs) with enhanced imaging contrast and reduced patient radiation burden. It is based on bioorthogonal chemistry with the tetrazine ligation-a reaction between trans-cyclooctenes (TCOs) and tetrazines (Tzs)-currently being the most popular reaction due to its high selectivity and reactivity. As Abs can be designed to bind specifically to currently 'undruggable' targets such as protein isoforms or oligomers, which play a crucial role in neurodegenerative diseases, pretargeted imaging beyond the BBB is highly sought after, but has not been achieved yet. A challenge in this respect is that large molecules such as Abs show poor brain uptake. Uptake can be increased by receptor mediated transcytosis; however, it is largely unknown if the achieved brain concentrations are sufficient for pretargeted imaging. In this study, we investigated whether the required concentrations are feasible to reach. As a model Ab, we used the bispecific anti-amyloid beta (Aβ) anti-transferrin receptor (TfR) Ab 3D6scFv8D3 and conjugated it to a different amount of TCOs per Ab and tested different concentrations in vitro. With this model in hand, we estimated the minimum required TCO concentration to achieve a suitable contrast between the high and low binding regions. The estimation was carried out using pretargeted autoradiography on brain sections of an Alzheimer's disease mouse model. Biodistribution studies in wild-type (WT) mice were used to correlate how different TCO/Ab ratios alter the brain uptake. Pretargeted autoradiography showed that increasing the number of TCOs as well as increasing the TCO-Ab concentration increased the imaging contrast. A minimum brain concentration of TCOs for pretargeting purposes was determined to be 10.7 pmol/g in vitro. Biodistribution studies in WT mice showed a brain uptake of 1.1% ID/g using TCO-3D6scFv8D3 with 6.8 TCO/Ab. According to our estimations using the optimal parameters, pretargeted imaging beyond the BBB is not a utopia. Necessary brain TCO concentrations can be reached and are in the same order of magnitude as required to achieve sufficient contrast. This work gives a first estimate that pretargeted imaging is indeed possible with antibodies. This could allow the imaging of currently 'undruggable' targets and therefore be crucial to monitor (e.g., therapies for intractable neurodegenerative diseases).

OriginalsprogEngelsk
TidsskriftPharmaceuticals (Basel, Switzerland)
Vol/bind15
Udgave nummer10
ISSN1424-8247
DOI
StatusUdgivet - 27 sep. 2022

ID: 85484302